CreatorsPublishersAdvertisers
View more in
Cancer

Pralsetinib Elicits Promising Activity in Advanced RET Fusion+ NSCLC

onclive.com
 2021-09-08

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies. In patients with advanced RET fusion–positive non-small cell lung cancer (NSCLC), pralsetinib (Gavreto) demonstrated promising results regardless of previous therapies, according to data from the Chinese cohort of the global ARROW study (BLU-667-1101;...

www.onclive.com

Comments / 0

Comments / 0